Economic Benefit of Aflibercept 8 mg Versus Faricimab for Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema in the US
For both nAMD and DME, less frequent dosing with aflibercept 8 mg versus faricimab is expected to reduce the direct and indirect cost burden to payers and patients.
Authors
- Hector Toro‐Díaz
- Steven Sherman (ORCID: https://orcid.org/0000-0002-8608-6575)
- Anna Coughlan
- Andreas Kuznik (ORCID: https://orcid.org/0000-0002-8634-8360)
- Nimesh Patel (ORCID: https://orcid.org/0000-0002-6021-9421)
- Amy Pinsent
Institutions
- Massachusetts Eye and Ear Infirmary (US)
- Boston Children's Hospital (US)
- Harvard University (US)
- Regeneron (United States) (US)
- Thermo Fisher Scientific (United Kingdom) (GB)
- Thermo Fisher Scientific (United States) (US)
Publication Details
- Journal
- Ophthalmology and Therapy
- Published
- 2025-09-19
- DOI
- https://doi.org/10.1007/s40123-025-01236-6
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00